Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study
{{output}}
Background: Although CD19 and CD22 chimeric antigen receptor (CAR-T) cell therapies have demonstrated encouraging clinical responses in patients with B-cell lymphoma, over 50% of patients ultimately experience disease progression... ...
